The addition of ARRA funds will be utilized for synthesis and acquisition of the anticancer agent known in the literature;those can be further studied in the NCI's anticancer program. The mission of the Developmental Therapeutics Program (DTP) is the development of novel synthetic and characterized natural products as potential anti-cancer agents. Towards this mission the contract will be devoted to the synthesis of small molecules needed by the various programs of the Division of Cancer Treatment and Diagnosis (DCTD), and other NIH divisions. This contract will provide essential synthesis support for the early stages of the drug development program. The small molecules assigned for the syntheses encompass a variety of structural classes;e.g., carbocyclics, heterocyclics, steroid analogs, and natural products. They originate from the NExT initiative of the DCTD, Biological Evaluation Committee (BEC), and other NCI, and NIH programs. Under the scope of the these programs, the synthesis of a limited series of analogs in order to improve the potencies and pharmacodynamic properties of the lead compound, where the core chemistry is either well established or less documented, were also undertaken. The remaining 10% of the work has originated other NCI, NIH programs. The purity and identity of all resynthesized compounds and intermediates were established by state-of-the-art physico-chemical methods. The quantities synthesized would vary from 200 mg to 100 grams. The overall objective of the contract will be the ?Non-GMP? chemical synthesis of compounds of good purity needed for the cancer NExT program, and compounds arising from recommendation of the Biological Evaluation Committee. The new contract will be utilized for the purpose of synthesis of active single compound leads and their analogs using parallel synthesis methodology, as sometimes required by the NCI programs.
